MarketFriction

Viyash Scientific Ltd

NSE VIYASH · BSE 512529 · Pharmaceuticals
₹231.75 -1.72%
NSE close2026-10-01
52 week range178.13 - 298.00
Market cap₹10,513 Cr.
P/E47.4
Microcap 250 Price band 20% Delivery 60.9%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales346329361390369774402792850858920946
Expenses331307329348330674355673677683736768
Operating Profit152232423910046119173176184178
OPM %4.4%7%9%11%11%13%12%15%20%20%20%19%
Other Income107-1304166-27168
Interest131312161421152018171513
Depreciation151516161758165659596062
Profit before tax-31312824164810273125112
Tax %123%-617%52%24%20%-71%36%24%29%34%47%29%
Net Profit-71119642103773496679
EPS in Rs-0.340.33-0.040.260.101.780.371.272.180.881.191.51
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6066848481,0391,1791,3621,4131,4211,3703,0073,4203,575
Expenses5506417659141,0091,1501,3031,4091,3082,6202,7682,864
Operating Profit5643831251702121091261387653711
OPM %9%6%10%12%14%16%8%0.8%4.5%13%19%20%
Other Income149436910-011-58-6-49-13
Interest382833333624163648866961
Depreciation464041425151525662239234240
Profit before tax-14-17444599413753-138-5513349413
Tax %19%-3%3%3%13%24%15%-11%-46%-20%36%
Net Profit-16-16431578210445-122-3016225267
EPS in Rs-0.78-0.5717.301.972.813.841.65-4.86-1.440.934.065.76
Dividend Payout %0%0%1%10%0%13%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth19%20%34%53%
Compounded Profit Growth28%15%73%148%
Stock Price CAGR7%2%37%28%
Return on Equity8%3%4%7%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital304849494950505050505087
Reserves618989285996576376786426496072,3822,824
Borrowings473312416305325343277365444488654490
Other Liabilities3432655033803464243813783743891,0421,195
Total Liabilities9081,5231,8961,3321,3781,4541,3861,4351,5171,5344,1284,596
Fixed Assets4745866844764985775365646055922,1032,103
CWIP392433182313311255164370
Investments5942842823918017183380400
Other Assets3364857515996776937378218569221,9812,422
Total Assets9081,5231,8961,3321,3781,4541,3861,4351,5171,5344,1284,596
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-24-0-745116115115311731345323
Cash from Investing Activity-157-310-1167-68-7210-94-65-6-448-84
Cash from Financing Activity179309147-57-20-43-1396732-187-123
Net Cash Flow-1-224-5280-144-1623-16115
Free Cash Flow-137-63-820927570-1-5819258225
CFO/OP-143%-3%5%65%92%75%75%52%263%73%102%59%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9511613611198999385888998112
Inventory Days153164165125134132139160152166169188
Days Payable147175208127141133119119107121121140
Cash Conversion Cycle101105931109298112126132135146160
Working Capital Days-11165-252033295154463074111
ROCE %8%2%1%40%9%12%16%6%-3%0%8%13%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters52.79%52.79%52.79%52.78%52.76%52.61%52.61%52.61%52.33%61.41%61.31%61.31%
FIIs6.03%6.12%6.16%5.69%6.45%6.10%6.05%6.15%5.90%3.16%2.94%4.50%
DIIs3.23%7.23%7.59%8.06%9.99%12.01%12.82%12.98%12.91%7.36%7.98%3.76%
Public37.57%33.69%33.29%33.30%30.63%29.12%28.36%28.10%28.69%27.97%27.67%30.34%
Others0.39%0.17%0.17%0.17%0.17%0.16%0.16%0.16%0.16%0.09%0.09%0.09%
No. of Shareholders1,84,5211,72,8531,66,5931,63,6931,54,6031,62,5741,58,1521,47,3201,44,0851,34,1941,27,4461,28,367

Fundamentals

Market Cap₹ 10,513 Cr.
Current Price₹ 238
Stock P/E47.4
Book Value₹ 66.6
ROCE13.4 %
ROE7.39 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)53%
Compounded Profit Growth (TTM)148%
Consolidated figures.
Valuation
Market capRs 10,124 Cr
Enterprise valueRs 10,344 Cr
P/E (TTM)47.91x
Price to book3.48x
Price to sales2.83x
EV / EBITDA14.48x
EV / EBIT21.81x
EV / sales2.89x
Price to cash flow31.35x
Earnings yield2.09%
P/E, 3-year average93.03x
P/B, 3-year average2.83x
P/E, 5-year average89.07x
P/B, 5-year average3.17x
Profitability
Operating margin (excl. other income)19.08%
Operating margin (incl. other income)19.06%
EBITDA margin19.98%
Pre-tax margin11.55%
Net profit margin5.91%
Net margin, latest quarter6.96%
ROE6.64%
ROCE12.90%
ROA4.06%
ROE, 3-year average0.95%
ROCE, 3-year average5.68%
ROA, 3-year average0.84%
ROE, 5-year average-1.76%
ROCE, 5-year average2.88%
ROA, 5-year average-0.55%
ROIC (approx.)9.75%
Tax rate35.63%
Other income / net worth-0.02%
Growth
Sales growth (latest year)13.75%
Profit growth (latest year)663.52%
Sales CAGR, 3 years34.02%
Sales CAGR, 5 years20.23%
Profit CAGR, 5 years13.19%
Sales growth QoQ2.87%
Profit growth QoQ26.41%
Sales growth YoY (latest quarter)19.54%
Profit growth YoY (latest quarter)107.07%
Per share
EPS (TTM)Rs 4.84
EPS (latest year)Rs 4.06
EPS (latest quarter)Rs 1.51
EPS, 3-year averageRs 1.18
EPS, 5-year averageRs 0.07
Book value per shareRs 66.64
Sales per shareRs 81.84
Cash flow per shareRs 7.39
Free cash flow per shareRs 5.15
Efficiency
Asset turnover0.74x
Fixed asset turnover1.63x
Inventory turnover2.33x
Inventory days157 days
Debtor days112 days
Debtors turnover3.27x
Creditor days140 days
Cash conversion cycle160 days
Working capital days111 days
Leverage
Total debtRs 490 Cr
Cash and bankRs 270 Cr
Net debtRs 220 Cr
Debt to equity0.17x
Net debt / EBITDA0.31x
Interest coverage7.74x
Current ratio (filing 2026-03-31)2.38x
Quick ratio (filing 2026-03-31)1.53x
Trade payables (filing 2026-03-31)Rs 597 Cr
Owners' fund to total sources63.34%
Debt to assets10.66%
Cash flow
Cash from Operating Activity (latest year)Rs 323 Cr
Cash from Investing Activity (latest year)Rs -84 Cr
Cash from Financing Activity (latest year)Rs -123 Cr
Net Cash Flow (latest year)Rs 115 Cr
Free cash flow (latest year)Rs 225 Cr
FCFE (approx.: FCF + change in debt)Rs 60 Cr
Cash from ops / profit, 5 years5.57x
Sales to cash flow10.59x
Statement figures
Net sales (TTM)Rs 3,575 Cr
Net sales (latest year)Rs 3,420 Cr
Sales (latest quarter)Rs 946 Cr
Operating profit excl. other income (latest year)Rs 653 Cr
Operating profit (latest quarter)Rs 178 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 714 Cr
PBDT (TTM)Rs 653 Cr
Profit before tax (TTM)Rs 413 Cr
Tax (latest year)Rs 124 Cr
Net profit (TTM)Rs 211 Cr
Net profit (latest year)Rs 177 Cr
Net profit (latest quarter)Rs 66 Cr
Depreciation (TTM)Rs 240 Cr
Depreciation (latest quarter)Rs 62 Cr
Interest (TTM)Rs 61 Cr
Cost of goods sold (latest year)Rs 1,870 Cr
Total expenditure (latest year)Rs 2,768 Cr
Total income (latest year)Rs 3,420 Cr
Share capitalRs 87 Cr
ReservesRs 2,824 Cr
Shareholders' fundsRs 2,911 Cr
Total assetsRs 4,596 Cr
Net blockRs 2,103 Cr
Capital work in progressRs 70 Cr
InvestmentsRs 0 Cr
ReceivablesRs 1,045 Cr
InventoryRs 803 Cr
Other liabilitiesRs 1,195 Cr
Shares outstanding (crore)43.69
Ownership
Promoter holding61.31% (+8.70 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 47.9 is at the 15th percentile of its own 6.8-year range (median 72.5, low 5.1, high 182.4).
P/B 3.48 is at the 9th percentile (median 5.53).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodVIYASHNifty 50Difference
1 week-5.8%-2.8% -3.0 pts
1 month-11.6%-6.8% -4.9 pts
3 months-21.2%-7.6% -13.6 pts
6 months+26.8%+0.4% +26.4 pts
1 year+19.2%-9.9% +29.2 pts
2 years+29.4%-13.6% +43.0 pts
3 years+150.1%+14.2% +136.0 pts
5 years+8.3%+27.9% -19.6 pts
25 mutual fund schemes hold about ₹686 Cr. Over three months 23 bought more and 2 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Kotak Multi Asset Allocation Fund0.78%120 +100%
Edelweiss Small Cap Fund1.31%95 +100%
Kotak ELSS Tax Saver Fund1.45%93 +100%
Bandhan Large & Mid Cap Fund0.36%76 +100%
Kotak Contra Fund0.95%52 +100%
Kotak Manufacture in India Fund1.75%52 +100%
Kotak Special Opportunities Fund1.97%33 +100%
Kotak MNC Fund1.41%33 +100%
Kotak Balanced Advantage Fund0.17%30 +100%
Kotak Consumption Fund1.52%26 +100%
UTI Healthcare Fund1.54%22 -16%
Bandhan Mid Cap Fund0.55%14 +100%
Kotak Healthcare Fund2.01%14 +100%
Motilal Oswal Nifty Microcap 250 Index Fund0.43%11 +13%
Bandhan Balanced Advantage Fund0.25%6 +100%
Bandhan Business Cycle Fund0.51%6 +100%
Bandhan Healthcare Fund0.85%3 +198%
Samco Multi Cap Fund0.50%1 +100%
Groww Nifty Total Market Index Fund0.02%0 +21%
Bandhan BSE Healthcare Index Fund0.25%0 +16%
Angel One Nifty Total Market Index Fund0.02%0 +15%
Mirae Asset Nifty Total Market Index Fund0.02%0 +15%
Bandhan Nifty Total Market Index Fund0.02%0 +21%
Motilal Oswal BSE 1000 Index Fund0.02%0 +21%
Quant Small Cap Fund0.00%0 -100%

Red flags

F-score 7 of 8
explainShare dilution Share count up 75% in a year, 75% in three
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹946 Cr +19.4% vs Jun 2025. Net profit ₹79 Cr +113.5%.
Against our estimate for Jun 2026: sales -25.3%, profit -3.2% in line. Our estimate for Sep 2026: sales Rs 1,360 Cr, profit Rs 106 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2021-09-08 Dividend - Rs 0.50 Per Share
2019-08-21 Annual General Meeting/Dividend - Rs 0.20 Per Share
2018-04-06 Scheme Of Arrangement
2017-11-20 Interim Dividend - Re 0.20 Per Share
2016-09-15 Annual General Meeting
DateTypeWhat it says
2026-10-01AcquisitionCompletion of acquisition of BioForLife Italia S.r.l
2026-09-18General UpdatesAllotment of ESOP
2026-09-08General UpdatesUpdate on proposed acquisition of BioForLife Italia S.r.l
2026-09-04General UpdatesESOP Allotment
2026-08-16Concall / analyst meetTranscript
2026-08-12Concall / analyst meetLink of Earning call Recording
2026-08-12Investor PresentationInvestor Presentation
2026-08-11Shareholder meetingVoting results.
2026-08-11Shareholder meetingProceedings of Annual General Meeting held on August 11, 2026
2026-08-11Press ReleaseA press release dated August 11, 2026, titled "Press Release for Q1 FY 2026-27".
2026-08-11General UpdatesGeneral Updates Allotment of ESOP under Viyash Scientific Limited -Employee Stock Option Scheme 2026
2026-08-11Board meeting outcomeViyash Scientific Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-03Concall / analyst meetSchedule of meet
2026-08-01General UpdatesESOP Allotment
2026-07-21General UpdatesGeneral Updates - Intimation under Regulation 30 of SEBILODR
2026-07-17General UpdatesLetter to the shareholder
2026-07-17UpdatesBusiness Responsibility and Sustainability Report for the Financial Year 2025-26.
2026-07-17Shareholder meetingNotice of Annual General Meeting to be held on August 11, 2026
2026-07-07General UpdatesDisclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-07-06Disclosure under SEBI TakeovCA Harbor Investments and CA Hull Investments has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange...
2026-06-29Shareholder meetingVoting results.
2026-06-25Concall / analyst meetPresentation
2026-06-17Concall / analyst meetSchedule of meet
2026-06-08Press ReleaseA press release dated Jun 08, 2026.
2026-06-08General UpdatesGeneral Updates-Acquisition
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-05-13NCLTSequent Scientific Ltd Vs Vidhya Pharmachem Pvt.Ltd
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Viyash Scientific Ltd?

Viyash Scientific Ltd (VIYASH) has a market capitalisation of Rs 10,513 Cr. at the 2026-10-01 close.

What is the P/E ratio of Viyash Scientific Ltd?

Viyash Scientific Ltd trades at a P/E of 47.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Viyash Scientific Ltd's latest quarterly results?

In the Jun 2026 quarter, Viyash Scientific Ltd sales was Rs 946 Cr (+19.4% vs Jun 2025) and net profit was Rs 79 Cr.

What is the 52-week high and low of Viyash Scientific Ltd?

The 52-week high is Rs 298.00 and the 52-week low is Rs 178.13.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03